<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557749</url>
  </required_header>
  <id_info>
    <org_study_id>2017NTLS045</org_study_id>
    <secondary_id>MT2017-12</secondary_id>
    <nct_id>NCT03557749</nct_id>
  </id_info>
  <brief_title>Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies</brief_title>
  <official_title>Monitoring of Immune and Microbial Reconstitution in Hematopoietic Cell Transplantation (HCT) and Novel Immunotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue
      samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and
      their donors at the Masonic Cancer Center in order to conduct correlative studies of the
      immune system, microbiota, and their interactions. Fluid (including but not limited to,
      blood, urine, saliva, cerebrospinal fluid, bronchoalveolar lavage fluid) sample log-in,
      processing, relabeling, and storage is performed by the Masonic Cancer Center (MCC)
      Translational Therapy Lab (TTL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of neutrophil recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of lymphocyte and monocyte subset recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of grade II-IV acute GVHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of CMV reactivation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of neutrophil recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of lymphocyte and monocyte subset recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function after Cell Therapy/Immunotherapy</measure>
    <time_frame>7 Years</time_frame>
    <description>Incidence of cytokine release syndrome (CRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate Immune Parameters</measure>
    <time_frame>7 Years</time_frame>
    <description>Correlate the lymphocyte phenotypes, specifically natural killer cell subsets and lymphocyte response to viral antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate microbiota changes and their interactions with the host with outcomes of HCT</measure>
    <time_frame>7 Years</time_frame>
    <description>Correlate microbiota changes and their interactions with the host with outcomes of HCT</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Immune and Microbial Reconstitution</condition>
  <condition>Systemic Viral Infection</condition>
  <condition>Acute-graft-versus-host Disease</condition>
  <condition>Chronic Graft-versus-host-disease</condition>
  <condition>Recurrent Malignancy</condition>
  <condition>Cytokine Release Syndrome</condition>
  <condition>Allogenic Related Donors</condition>
  <condition>Cell Therapy/Immunotherapy Patients</condition>
  <arm_group>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Relapse</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Response Triggered by Cytokine Release Syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>60 ml heparinized blood 10 ml serum</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Cytokine Release Syndrome</arm_group_label>
    <arm_group_label>Immune Response Triggered by Relapse</arm_group_label>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stool Sample</intervention_name>
    <description>pea-sized amount</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine Sample</intervention_name>
    <description>10 ml</description>
    <arm_group_label>Allogeneic Related Donor Samples</arm_group_label>
    <arm_group_label>Immune and Microbial Reconstitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchoalveolar Lavage (BAL) fluid</intervention_name>
    <description>10 ml</description>
    <arm_group_label>Immune Response Triggered by Severe, Systemic Viral Infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gastrointestinal biopsy x 2-4</intervention_name>
    <description>rectosigmoid site preferred</description>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>2-4 mm punch</description>
    <arm_group_label>Immune Response Triggered by Acute Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin, mouth, and/or ocular swab</intervention_name>
    <description>Involved skin, mouth, and/or ocular swab for microbiota studies</description>
    <arm_group_label>Immune Response Triggered by Chronic Graft-versus-Host Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Apheresis Product</intervention_name>
    <description>Up to 10 ml of apheresis product</description>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Final cellular product</intervention_name>
    <description>A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product</description>
    <arm_group_label>Cellular Therapy Products</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving care in the University of Minnesota Blood and Marrow Transplant
        Program
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients planning to undergo HCT or other cellular therapy/immunotherapy

          -  Allogeneic related donors

          -  Aged 0-80

          -  Willing and able to sign voluntary written consent

        Exclusion Criteria:

          -  Patients whose medical record indicates that they have opted out of research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy Krepsky, RN</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.rog</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shernan Holtan, MD</last_name>
    <phone>612-301-1095</phone>
    <email>sgholtan@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shernan Holtan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

